Interview with P.F. Bongers, Chairman, Bogin
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
Address: Minervum 7061, 4817 ZK, Breda,Netherlands
Tel: 076-5732500
Web: http://www.amgen.nl/dutch/index.html
Sinds 1997 levert Amgen vanuit Breda haar producten door heel Europa en aan een groeiend aantal landen in andere delen van de wereld. We verpakken medicijnen landenspecifiek, slaan ze tijdelijk op en verschepen uiteindelijk naar meer dan 50 landen.
Voor Amgen Europe B.V. geldt: “Elke patiënt, telkens weer”. Hiermee bedoelen we dat we ernaar streven om onze producten altijd beschikbaar te hebben op de juiste plaats en op de juiste tijd voor de behandeling van de patiënt. Vanuit Breda distribueren we zowel geregistreerde producten als producten die gebruikt worden in klinisch onderzoek. Breda is ook de vestigingsplaats van twee onderdelen van de Global Supply Chain organisatie verantwoordelijk voor Europa, Afrika en Australië/Nieuw-Zeeland. Daarnaast is Amgen Breda het internationale centrum buiten de Verenigde Staten voor enkele andere functies, zoals Quality & Regulatory Compliance, Information Systems en Financial Shared Services.
Circa 500 gemotiveerde mensen werken samen in hun streven naar perfectie in hun werkzaamheden, met als uiteindelijke doel het verbeteren van mensenlevens.
Amgen has marketed various key breakthrough products including Aranesp, Neulasta, Neupogen, Mimpara en Nplate all of which have made a vital contribution to patients’ welfare. Amgen’s future aims will also remain centred on finding innovative solutions for patients. This is why Amgen continues to develop new products for syndromes where treatment options are insufficient.
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you doubled the size of…
Founded in 1997 Actelion is certainly the “new kid on the block” when compared to some of the much older mainstays in the pharmaceutical industry. What would you say was…
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
See our Cookie Privacy Policy Here
